138 related articles for article (PubMed ID: 15032612)
1. Fas ligand gene therapy for vascular intimal hyperplasia.
Jiang C; Yang YF; Cheng SH
Curr Gene Ther; 2004 Mar; 4(1):33-9. PubMed ID: 15032612
[TBL] [Abstract][Full Text] [Related]
2. Expression of wild-type and noncleavable Fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions.
Mano T; Luo Z; Suhara T; Smith RC; Esser S; Walsh K
Hum Gene Ther; 2000 Aug; 11(12):1625-35. PubMed ID: 10954897
[TBL] [Abstract][Full Text] [Related]
3. Fas ligand/Fas-mediated apoptosis in human coronary artery smooth muscle cells: therapeutic implications of fratricidal mode of action.
Belanger AJ; Scaria A; Lu H; Sullivan JA; Cheng SH; Gregory RJ; Jiang C
Cardiovasc Res; 2001 Sep; 51(4):749-61. PubMed ID: 11530108
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals.
Luo Z; Sata M; Nguyen T; Kaplan JM; Akita GY; Walsh K
Circulation; 1999 Apr; 99(14):1776-9. PubMed ID: 10199871
[TBL] [Abstract][Full Text] [Related]
5. Role of endogenous Fas (CD95/Apo-1) ligand in balloon-induced apoptosis, inflammation, and neointima formation.
Matter CM; Chadjichristos CE; Meier P; von Lukowicz T; Lohmann C; Schuler PK; Zhang D; Odermatt B; Hofmann E; Brunner T; Kwak BR; Lüscher TF
Circulation; 2006 Apr; 113(15):1879-87. PubMed ID: 16606788
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death: implications for vascular disease and therapy.
Sata M; Suhara T; Walsh K
Arterioscler Thromb Vasc Biol; 2000 Feb; 20(2):309-16. PubMed ID: 10669625
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of Fas ligand-induced inhibition of neointimal formation in rabbit femoral and iliac arteries by coexpression of p35.
Luo Z; Garron T; Palasis M; Lu H; Belanger AJ; Scaria A; Vincent KA; Date T; Akita GY; Cheng SH; Barry J; Gregory RJ; Jiang C
Hum Gene Ther; 2001 Dec; 12(18):2191-202. PubMed ID: 11779403
[TBL] [Abstract][Full Text] [Related]
8. Intimal hyperplasia: slow but deadly.
Mills B; Robb T; Larson DF
Perfusion; 2012 Nov; 27(6):520-8. PubMed ID: 22751382
[TBL] [Abstract][Full Text] [Related]
9. Update on gene therapy for intimal hyperplasia.
Reis ED; Skladany M
Bratisl Lek Listy; 1999 Aug; 100(8):417-21. PubMed ID: 10645028
[TBL] [Abstract][Full Text] [Related]
10. Fas ligand-deficient mice display enhanced leukocyte infiltration and intima hyperplasia in flow-restricted vessels.
Sata M; Walsh K
J Mol Cell Cardiol; 2000 Aug; 32(8):1395-400. PubMed ID: 10900166
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of intimal hyperplasia by gene therapy: an update].
Reis E; Martinet O; Mosimann F
J Mal Vasc; 1999 Dec; 24(5):349-55. PubMed ID: 10642646
[TBL] [Abstract][Full Text] [Related]
12. Salusin-β Promotes Vascular Smooth Muscle Cell Migration and Intimal Hyperplasia After Vascular Injury via ROS/NFκB/MMP-9 Pathway.
Sun HJ; Zhao MX; Ren XS; Liu TY; Chen Q; Li YH; Kang YM; Wang JJ; Zhu GQ
Antioxid Redox Signal; 2016 Jun; 24(18):1045-57. PubMed ID: 26952533
[TBL] [Abstract][Full Text] [Related]
13. Acute and chronic smooth muscle cell apoptosis after mechanical vascular injury can occur independently of the Fas-death pathway.
Sata M; Sugiura S; Yoshizumi M; Ouchi Y; Hirata Y; Nagai R
Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1733-7. PubMed ID: 11701458
[TBL] [Abstract][Full Text] [Related]
14. SHP-1 activation inhibits vascular smooth muscle cell proliferation and intimal hyperplasia in a rodent model of insulin resistance and diabetes.
Qi W; Li Q; Liew CW; Rask-Madsen C; Lockhart SM; Rasmussen LM; Xia Y; Wang X; Khamaisi M; Croce K; King GL
Diabetologia; 2017 Mar; 60(3):585-596. PubMed ID: 27933336
[TBL] [Abstract][Full Text] [Related]
15. p27-p16 fusion gene inhibits angioplasty-induced neointimal hyperplasia and coronary artery occlusion.
Tsui LV; Camrud A; Mondesire J; Carlson P; Zayek N; Camrud L; Donahue B; Bauer S; Lin A; Frey D; Rivkin M; Subramanian A; Falotico R; Gyuris J; Schwartz R; McArthur JG
Circ Res; 2001 Aug; 89(4):323-8. PubMed ID: 11509448
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-Like Peptide-1 Receptor Activation Does not Affect Re-Endothelialization but Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Nondiabetic Model of Arterial Injury.
Eriksson L; Saxelin R; Röhl S; Roy J; Caidahl K; Nyström T; Hedin U; Razuvaev A
J Vasc Res; 2015; 52(1):41-52. PubMed ID: 25966620
[TBL] [Abstract][Full Text] [Related]
17. Fas ligand and nitric oxide combination to control smooth muscle growth while sparing endothelium.
Kural MH; Wang J; Gui L; Yuan Y; Li G; Leiby KL; Quijano E; Tellides G; Saltzman WM; Niklason LE
Biomaterials; 2019 Aug; 212():28-38. PubMed ID: 31102854
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone.
Nagler A; Miao HQ; Aingorn H; Pines M; Genina O; Vlodavsky I
Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):194-202. PubMed ID: 9012656
[TBL] [Abstract][Full Text] [Related]
19. Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88: phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation.
Francis DJ; Parish CR; McGarry M; Santiago FS; Lowe HC; Brown KJ; Bingley JA; Hayward IP; Cowden WB; Campbell JH; Campbell GR; Chesterman CN; Khachigian LM
Circ Res; 2003 May; 92(8):e70-7. PubMed ID: 12690039
[TBL] [Abstract][Full Text] [Related]
20. Delivery of viral vectors for gene therapy in intimal hyperplasia and restenosis in atherosclerotic swine.
Hall S; Agrawal DK
Drug Deliv Transl Res; 2018 Aug; 8(4):918-927. PubMed ID: 28707263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
